Table 2.
Use of Cohen’s d in studies of stimulants and nonstimulants in children, adolescents, and adults with ADHD, major depressive episode, and dysthymic disorder*
| STUDY | TREATMENT, SUBJECTS, AND SCALESa | COHEN’S d |
|---|---|---|
| Biederman et al, 2003 (2 weeks)8 | XR-MPH (n=65) vs. placebo (n=71). Children. Conners ADHD/DSM-IV Scale | 0.9 |
| Faraone and Schreckengost, 2007 (4 weeks)9 | Lisdexamfetamine (n=218) vs. placebo (n=72). Children. ADHD Rating Scale | 30mg, 1.4 50mg, 1.4 70mg, 1.7 |
| Faraone et al, 2004 (meta-analysis of 6 studies)10 | IR-MPH (n=139) vs. placebo (n=113). Adults. 4 crossover, 2 parallel studies. ADHD Rating Scale | Crossover, 0.9; Parallel, 0.7 |
| Faraone et al, 2002 (meta-analysis of 4 studies)11 | IR-MAS (n=108) vs. IR-MPH (n=108). Children and adolescents. IOWA Conners Rating Scale, ADHD Rating Scale, global scale | 0.25 (pooled); range, –0.5–1.0 |
| Kelsey et al, 2004 (8 weeks)12 | Atomoxetine (n=133) vs. placebo (n=64). Children. ADHD Rating Scale | 0.7 |
| McGough et al, 2006 (1 week)13 | Transdermal MPH vs. transdermal placebo (N=79). Children. Crossover study. SKAMP deportment scale | 0.9 |
| Michelson et al, 2002 (6 weeks)14 | Atomoxetine (n=85) vs. placebo (n=85). Children and adolescents. ADHD Rating Scale | 0.7 |
| Michelson et al, 2003 (10 weeks)15 | Study 1, atomoxetine (n=141) vs. placebo (n=139); Study 2, atomoxetine (n=129) vs. placebo (n=127). Adults. Conners Adult ADHD Rating Scale | Study 1, 0.4; Study 2, 0.4 |
| Pelham et al, 2001 (7 days)16 | OROS-MPH vs. IR-MPH (N=68). Children. Crossover study. IOWA Conners Rating Scale | 2.0 |
| Spencer et al, 2002 (12 weeks)17 | Atomoxetine (n=129) vs. placebo (n=124). Children. ADHD Rating Scale | 0.7 |
| Swanson et al, 2003 (7 days)18 | OROS-MPH or IR-MPH vs. placebo (n=64). Children. Crossover study. IOWA Conners Rating Scale | OROS-MPH, 1.7; IR-MPH, 1.6 |
| Weisler et al, 2006 (4 weeks)19 | XR-MAS (n=188) vs. placebo (n=60). Adults. ADHD Rating Scale | 0.8 |
| Wigal et al, 2005 (3 weeks)20 | XR-MAS (n=102) vs. atomoxetine (n=101). Children. SKAMP deportment scale | XR-MAS, 1.1; atomoxetine, 0.2 |
| Wilens et al, 2005 (8 weeks)21 | XR-bupropion (n=81) vs. placebo (n=81). Adults. ADHD Rating Scale | 0.6 |
| Wolraich et al, 2001 (1–4 weeks)22 | OROS-MPH (n=95) or IR-MPH (n=97) vs. placebo (n=90). Children. IOWA Conners Rating Scale | OROS-MPH, 1.1; IR-MPH, 1.0 |
a
All were parallel studies unless noted otherwise.
- ADHD
attention-deficit/hyperactivity disorder
- DSM-IV
Diagnostic and Statistical Manual, Fourth Edition
- IOWA
Inattention and Overactivity With Aggression
- IR
immediate release
- MAS
mixed amphetamine salts
- MPH
methylphenidate
- OROS
osmotic-release oral system
- SKAMP
Swanson, Kotkin, Agler, M-Flynn, and Pelham
- XR
extended-release